Not yet recruitingPhase 2NCT05507632

Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma

Studying Pediatric hepatocellular carcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Nanfang Hospital, Southern Medical University
Principal Investigator
Jinzhang Chen
Nanfang Hostipal of Southern Medical University
Intervention
Donafenib plus Sintilimab in combination with transarterial chemoembolisation(combination_product)
Enrollment
48 enrolled
Eligibility
18-75 years · All sexes
Timeline
2022 – 2026

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05507632 on ClinicalTrials.gov

Other trials for Pediatric hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Pediatric hepatocellular carcinoma →

← Back to all trials